GlobeNewswire by notified

Havila Kystruten AS: Fourth quarter 2023 accounts



The company has completed its first quarter with full operation of all four ships. Revenue in the fourth quarter was MNOK 249. Due to late clarification on the delivery of the last two ships, the revenue side is somewhat lower than if the pre-sale had started earlier.

The last quarter of 2023 ended with an average fleet occupancy of 60%, an average cabin rate (ACR) of NOK 3,100 and a utilization rate of 1.8 per cabin.

Occupancy and average price per cabin are higher than the fourth quarter of 2022, but are somewhat lower than the third quarter due to lower demand in the autumn and winter months. EBITDA was negative by MNOK 33.2 in the fourth quarter and MNOK 179 for the full year.

Operating costs amounted to MNOK 283 in the fourth quarter and are mainly ordinary operating costs for operating four ships. Some of the operating costs are related to the number of passengers, while the largest cost items are not significantly affected by occupancy.

MNOK 18 relates to extraordinary marketing costs to secure the pre-sale of the last two ships for the last quarter of 2023 and the first quarter of 2024.

LNG costs have also been somewhat higher in the period due to additional costs for securing prices in the market. Profit and loss and balance sheet are significantly affected by fluctuations in exchange rates, especially the value of the Norwegian krone against the euro since ship financing is in euros.

The fleet’s operational uptime was 99.2% for the fourth quarter and 99.5% for the year as a whole. The company’s target of less than 75g food waste per guest day was achieved for both the fourth quarter (60g) and the year as a whole (54g).

The company looks forward to 2024, which will be the company’s first year with all four ships in operation. Interest in Havila Kystruten is steadily increasing both domestically and internationally, and the company is receiving positive feedback on the product and concept. Based on a good trend in booking figures, of which 65% are sold for the first quarter and over 55% for 2024 in total, an average occupancy of just under 80% is expected for 2024.

In February 2024, the company secured a refinancing of a loan maturity of MEUR 50 in October 2024 by raising corresponding financing from Havila Holding AS, which runs until after the maturity of MEUR 255 in July 2026. A credit facility of MNOK 200 has also been made available, which gives the company financial flexibility to handle seasonal liquidity fluctuations.

Results for the fourth quarter of 2023

•             Revenue totaled MNOK 249, of which MNOK 82 was revenue from the Ministry of Transport and Communications.

•             Operating costs consisted of MNOK 38 in cost of goods sold, MNOK 86 in salary costs, and MNOK 159 in other operating costs.

•             Operating profit before depreciation was MNOK - 33.

•             Depreciation was MNOK 54.

•             Net financial items were MNOK - 195.

•             Profit before tax was MNOK - 282.

Results for 2023

•             Revenue totaled MNOK 764, of which MNOK 216 was revenue from the Ministry of Transport and Communications.

•             Operating costs consisted of MNOK 106 in cost of goods sold, MNOK 282 in salary costs, and MNOK 556 in other operating costs. LNG, port costs, and sales and marketing are the largest cost items within other operating costs, but costs for legal advisors are also significant until August.

•             Operating profit before depreciation was MNOK - 180.

•             Depreciation was MNOK 137.

•             Net financial items were MNOK - 546, of which MNOK 35 is unrealized exchange rate loss on financing.

•             Profit before tax was MNOK - 863.

Balance sheet and liquidity as of 31.12.2023

•             Total fixed assets were MNOK 4,337, of which ships accounted for MNOK 4,274, intangible assets accounted for MNOK 38, right-of-use of leased equipment accounted for MNOK 20 and operating equipment accounted for MNOK 5.

•             Current assets were MNOK 425, of which cash and cash equivalents accounted for MNOK 150, of which MNOK 10 are restricted funds for tax deductions.

•             Net cash flow from operating activities was MNOK -566. Cash flow from investing activities was MNOK -682. Net cash flow from financing activities was MNOK 1,095.

•             The carrying amount of long-term debt was MNOK 3,124. Of the ship financing, MNOK 582 was short-term as of December 31, 2023. An agreement has now been made for refinancing so that the debt will again be long-term upon completion.

•             Total current liabilities were MNOK 1,161, of which the main items are trade payables, debt to credit institutions as mentioned above and advances from customers.


Havila Kystruten had a total of 481 permanent employees as of December 31, 2023, of which 438 were seafarers and 43 were in administration.

Chief Executive Officer Bent Martini, +47 905 99 650
Chief Financial Officer Arne Johan Dale, +47 909 87 706


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Tryg A/S – Interim report Q1 202417.4.2024 07:30:00 CEST | Press release

Tryg’s Supervisory Board has today approved the Q1 2024 interim report. Tryg reported an insurance service result of DKK 1,275m (DKK 1,474m) and a combined ratio of 86.6 (84.0) in Q1 2024, adversely impacted by more than DKK 180m higher than normal weather and large claims level. The underlying claims ratio for the Group improved by 50bps, whilst the Private segment displayed a deterioration of 50bps driven by an increase in motor claims frequency. Tryg reported a top-line growth of 4.8% primarily driven by price increases to offset inflationary pressures. Synergies from the RSA Scandinavia acquisition were DKK 43m in the quarter and DKK 754m accumulated. The investment result was DKK 117m (DKK 167m) mainly impacted by positive returns from equities and covered bonds. Pre-tax profit was DKK 1,007m (DKK 1,187m) and profit after tax was DKK 776m. Quarterly dividend of DKK 1.95 (DKK 1.85) per share an increase of more than 5%, solvency ratio of 191 supportive of future shareholders' retur

Tryg A/S – 1. kvartals rapport 202417.4.2024 07:30:00 CEST | pressemeddelelse

Trygs bestyrelse har i dag godkendt 1. kvartals rapport for 2024 Tryg rapporterede et insurance service result på 1.275 mio. DKK (1.474 mio. DKK) og en combined ratio på 86,6 (84,0) i 1. kvartal 2024 påvirket negativt af højere end normalt vejr- og storskader niveau for mere end 180 mio. DKK. Den underliggende erstatningsprocent for Tryg Koncernen blev forbedret med 0,5 procentpoint, hvorimod Privat havde en forværring i den underliggende erstatningsprocent på 0,5 procentpoint påvirket af en stigning i frekvensen for motor skader. Tryg rapporterede en vækst på 4,8% i lokal valuta drevet af prisjusteringer for at imødegå effekten fra skadesinflationen. Synergier fra RSA Skandinavien transaktionen udgjorde 43 mio. DKK og 754 mio. DKK akkumuleret. Investeringsresultatet udgjorde 117 mio. DKK. (167 mio. DKK) og var primært påvirket af positive afkast på aktier og realkreditobligationer. Resultatet før skat udgjorde 1.007 mio. DKK (1.187 mio. DKK) og 776 mio. DKK efter skat. Udbyttet for kv

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis17.4.2024 07:15:00 CEST | Press release

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study1 Similar efficacy outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population2 Switch from teriflunomide to Kesimpta resulted in significant improvements across several efficacy outcomes such as annualized relapse rate and MRI lesion activity in both analyses1,2 Treatment with Kesimpta for up to six years continues to be well tolerated with consistent safety outcomes, supporting the favorable benefit-risk profile of Kesimpta in RMS2 Basel, April 17, 2024 – Novartis today announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta® (ofatumumab) treatment for up to six years in recently diagnosed – defined as s

Idorsia publishes a Financial Status required for an upcoming bondholder meeting17.4.2024 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company websiteBondholder meeting now planned for early May as the company continues to engage with bondholders Allschwil, Switzerland – April 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting is available on the company website at the following link: Idorsia continues to engage with bondholders on options and terms regarding the repayment of the convertible bond maturing on July 17, 2024 (ISIN: CH0426820350). As a result, the bondholder meeting initially contemplated for April 30, 2024, is expected to take place shortly thereafter. André C. Muller, Chief Financial Officer, commented: “We have had many interactions with our bondholders in the past week. We are finalizing our pr

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis17.4.2024 07:00:00 CEST | Press release

New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS Paris, April 17, 2024. Sanofi’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis. These data will be presented today at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, Colorado, US. Results from the 12-week double-blind study period were previously published in The New England Journal of Medicine. Patrick Vermersch, MD, PhD University of Lille,

HiddenA line styled icon from Orion Icon Library.Eye